Polyclonal Antibody to Selectin, Endothelium (SELE)
| Code | Size | Price |
|---|
| PAA029Rb51-20ul | 20ul | £86.00 |
Quantity:
| PAA029Rb51-100ul | 100ul | £158.00 |
Quantity:
| PAA029Rb51-200ul | 200ul | £214.00 |
Quantity:
| PAA029Rb51-1ml | 1ml | £488.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Guinea Pig
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Rabbit
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
CD62E; CD62-E; E-Selectin; ELAM; ELAM1; ESEL; SEL-E; E-LAM; E-LAM1; E-SEL; LECAM2; Endothelial Leukocyte Adhesion Molecule 1; CD62 Antigen-Like Family Member E
Buffer Formulation:
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Item Name:
E-selectin
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.2-2ug/mL;1:250-2500
Immunohistochemistry: 5-20ug/mL;1:25-100
Immunocytochemistry: 5-20ug/mL;1:25-100
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;1:25-100
Immunocytochemistry: 5-20ug/mL;1:25-100
Optimal working dilutions must be determined by end user.
References
https://onlinelibrary.wiley.com/doi/abs/10.1111/asj.13604;
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Selectin, Endothelium (SELE) | RPA029Rb01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||